Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3862995B in healthy participants of Chinese, Japanese, and European ancestry
NCT06979518Phase 1Completed
- Sponsor
- GSK
- Start
- May 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing GSK3862995B with Placebo (2 arms). Primary endpoints: Number of Participants with Adverse Events, Number of Participants with Serious Adverse Events and 5 more. Started May 2025; status: completed.
02
Drugs
gsk3862995b
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06979518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979518.